Match each clinical presentation of chronic liver disease to the most appropriate next ste… — USMLE Step 2 CK

Match each clinical presentation of chronic liver disease to the most appropriate next step in management or definitive therapy.

A 48-year-old woman presents with debilitating pruritus and fatigue. Physical examination shows xanthelasma. Labs reveal alkaline phosphatase $450$ U/L, total bilirubin $1.2$ mg/dL, and a positive anti-mitochondrial antibody titer.Initiation of ursodeoxycholic acid
A 30-year-old man with a history of ulcerative colitis presents with worsening fatigue and jaundice. Magnetic resonance cholangiopancreatography reveals alternating strictures and dilation of the intrahepatic and extrahepatic bile ducts.Endoscopic retrograde cholangiopancreatography with stricture dilation
A 25-year-old woman presents with lethargy and amenorrhea. Labs show aspartate aminotransferase $650$ U/L, alanine aminotransferase $720$ U/L, elevated total IgG, and positive anti-smooth muscle antibodies.Initiation of prednisone and azathioprine
A 58-year-old man presents with progressive joint pain in the 2nd and 3rd metacarpophalangeal joints, new-onset polyuria, and darkened skin. Labs show transferrin saturation of $65\%$ and ferritin of $1200$ ng/mL.Regular therapeutic phlebotomy
A 22-year-old man presents with progressive dysarthria, a resting tremor, and elevated aminotransferases. Slit-lamp examination reveals brown-green rings in the peripheral cornea. Labs show decreased serum ceruloplasmin.Initiation of oral D-penicillamine or trientine

Answer

Primary biliary cholangitis is treated with ursodeoxycholic acid; Primary sclerosing cholangitis strictures are managed with ERCP and dilation; Autoimmune hepatitis is treated with prednisone and azathioprine; Hemochromatosis requires therapeutic phlebotomy; Wilson disease requires D-penicillamine or trientine.

The correct matches align distinct clinical and serologic presentations of chronic hepatobiliary disorders to their specific, mechanism-directed therapies. Primary biliary cholangitis is managed with ursodeoxycholic acid to alter the bile acid pool and delay disease progression. Primary sclerosing cholangitis requires ERCP for dominant strictures to relieve obstruction. Autoimmune hepatitis necessitates immunosuppression to halt immune-mediated hepatocyte destruction. Hemochromatosis requires physical removal of excess total body iron through phlebotomy. Wilson disease requires copper chelation.

Step-by-Step Solution

Analyze the first vignette to identify the underlying disease mechanism.

Identified Primary Biliary Cholangitis (PBC) based on middle age, female sex, pruritus, positive AMA, and isolated elevated alkaline phosphatase.

Accurate diagnosis is required before selecting the specific pharmacologic or procedural intervention.

Analyze the remaining clinical vignettes for key diagnostic markers.

Identified PSC (ulcerative colitis history, MRCP showing beaded ducts), Autoimmune Hepatitis (ASMA positive, elevated IgG), Hemochromatosis (transferrin saturation > 45%, high ferritin, bronze diabetes), and Wilson disease (Kayser-Fleischer rings, low ceruloplasmin).

Each hepatobiliary pathology has a distinct serologic and demographic profile.

Select the definitive therapy or next best step for each identified pathology.

Matched PBC to ursodeoxycholic acid, PSC to ERCP stricture dilation, AIH to immunosuppression, Hemochromatosis to phlebotomy, and Wilson disease to copper chelation.

Therapies are highly specific to the pathophysiologic mechanism (e.g., removing excess iron, chelating copper, suppressing autoimmunity, altering bile acid composition).

Key Concept

Clinical presentation and specific therapeutic interventions for chronic hepatic and biliary diseases.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic